Cost of care for six months of preventive HAE therapy: $335,000 or more

Analysis of two preventive HAE drugs show they are overpriced, cost to value

January 21, 2020

Real-world integrated claims data from use of two preventive drugs for hereditary angioedema (HAE) show they are overpriced, cost to value¹

Two HAE preventive therapies came on the market since Prime’s HAE study in 2018:

  • Haegarda (C1-INH), launched June 22, 2017 and
  • Takhzyro (lanadelumab), launched August 23, 2018.

This gives members with HAE three treatment options for preventive care. (Cinzyre (C1-INH) is the third, and not part of this study.)

HAE is a extremely rare and potentially life-threatening genetic condition. Patients often use a combination of on-demand treatment and long-term preventive treatment.

Prime identified 58 members that qualified for the study criteria, out of its 15 million commercial members. To assess total cost of care, the study looked at integrated medical and pharmacy data for these members and their use of one of the two preventive care drugs. It also tracked their use and cost of additional on-demand HAE treatment drug therapy.

Comparison of six-month mean costs

Haegarda’s mean cost for six months was nearly $227,000. Takhzyro mean cost for six months was more than $278,000. That’s a difference of $51,000 (22%) for six months of treatment. Members taking Haegarda had a total six-month mean cost of $335,000 (which included additional on demand therapy and their Haegarda therapy). Takhzyro members had a total six-month mean cost of $361,000 (which included additional on-demand therapy plus their Takhzyro therapy).

A report from the Institute for Clinical and Economic Review indicates these drugs exceed thresholds for cost-effectiveness.¹

Prime’s proficiency in data analytics turns integrated benefits claims data into actionable, real world cost of care information. This can help inform preferred drug placement decision making and value-based contract negotiations with pharmaceutical manufacturers.


1. Institute for Clinical and Economic Review Issues Final Report on Long-Term Prophylaxis for Hereditary Angioedema, Provides Policy Recommendations to Improve Cost-Effectiveness. Nov. 15, 2018. Boston. © ICER, 2021. Accessed at:

Hereditary Angioedema (HAE) Real-World Prophylactic and On-demand Treatment Cost in a 15 Million Commercially Insured Population: Comparison of C-1 Inhibitor (Haegarda®) versus Lanadelumab (Takhzyro®) Treated Members (Spring 2020)
Hereditary Angioedema: A Comprehensive Integrated Medical and Pharmacy Claims Analysis of Utilization and Costs Among 15 Million Commercially Insured Members (Spring 2018)

Related news


March 30, 2023

Drug oversupply, or stockpiling, due to overlapping drug refills can cause unnecessary drug costs

If you have a chronic condition, your pharmacy may notify you advance of…


March 28, 2023

Biosimilars are at the door, Part 3

News about biosimilars is everywhere. Sometimes you just need the basics. This four-part…


March 27, 2023

Specialty Drug Pipeline Update: March 2023

This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…